Sorted By:

Relevance


The Power of Medicines

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/the-power-of-medicines

Chip Meyers, Jr.

PhRMA  |  Biography

They have three daughters and now make their home in Oakton, VA.
https://www.phrma.org/biography/chip-meyers-jr

Team PhRMA Raises $100,000 for Leukemia/Lymphoma Research

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.
https://www.phrma.org/press-release/team-phrma-raises-100-000-for-leukemia/lymphoma-research

Ask About Adherence: One tool for synchronizing and simplifying your medication routine

PhRMA  |  Blog Post

Here are some additional resources to check out to learn more about the importance of medication adherence and see if a program like med sync is right for you and your family.
http://catalyst.phrma.org/ask-about-adherence-one-tool-for-synchronizing-and-simplifying-your-medication-routine

Careers

PhRMA  |  From PhRMA

PhRMA’s current employment opportunities are listed below, and this listing is updated regularly.
https://www.phrma.org/about/careers

Letter to the Centers for Medicare and Medicaid Services (CMS) from PhRMA, AdvaMed, and BIO

PhRMA  |  Speeches & Communication

As life science trade associations representing thousands of medical device, biotechnology and pharmaceutical companies, we express our longstanding support for the goals of the Physician Payments Sunshine Act (“the Sunshine Act”), section 6002 of the Affordable Care Act of 2010, which will provide transparency in industry collaboration with teaching hospitals, physicians; and report physician ownership and investment interests.
https://www.phrma.org/letter-to-the-centers-for-medicare-and-medicaid-services-cms-from-phrma-advamed-and-bio/letter-to-the-centers-for-medicare-and-medicaid-services-cms-from-phrma-advamed-and-bio

Medicare Monday Then & Now: Beneficiary Premiums

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/medicare-monday-then-and-now-beneficiary-premiums

New Report Shows Past Drug Failures Aid in the Fight Against Cancer

PhRMA  |  Blog Post

Another report on innovation in the biopharmaceutical pipeline found that 80 percent of cancer medicines in the pipeline globally are potentially first-in-class treatments – meaning that they use a new and unique mechanism for treating a medical condition.
http://catalyst.phrma.org/new-report-shows-past-drug-failures-aid-in-the-fight-against-cancer

Costs and Consequences of Not Treating Diseases

PhRMA  |  Blog Post

We look forward to sharing more about the benefits of medicines and hope that you will share your thoughts to the comments section below.
http://catalyst.phrma.org/costs-and-consequences-of-not-treating-diseases

How biopharmaceutical collaboration is driving a new era of medicine

PhRMA  |  Blog Post

“I think it’s a golden age for therapeutic development right now and we have to be sure that our society understands how important it is that the investment continues to occur,” said Sean Harper, executive vice president, Amgen. 
http://catalyst.phrma.org/collaboration-driving-new-era-of-medicine

PhRMA Statement on Report President Commissions’ Final Report with Opioid Recommendations

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $65.5 billion in 2016 alone.
https://www.phrma.org/press-release/phrma-statement-on-report-president-commissions-final-report-with-opioid-recommendations

Data Sharing Commitments will Enhance Research and Scientific Knowledge, Advance Patient Care and Improve Public Health

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.
https://www.phrma.org/press-release/data-sharing-commitments-will-enhance-research-and-scientific-knowledge-advance-patient-care-and-improve-public-health

New Research Demonstrates Biopharmaceutical Sector’s Impact on U.S. Economy and Jobs

PhRMA  |  Press Release

We don’t believe policies that discourage R&D and cutting-edge science and that will inevitably slow the development of needed new medicines are fair for seniors waiting for new treatments against our most challenging and costly diseases.  
https://www.phrma.org/press-release/new-research-demonstrates-biopharmaceutical-sector-s-impact-on-u-s-economy-and-jobs

Big Profits Seen In Rare Diseases

From Hope To Cures  |  From Our Network

"There's more money, fewer patients, and it's 10 times easier to defend high prices to payers."
http://www.fromhopetocures.org/big-profits-seen-in-rare-diseases

Nearly 400 Medicines and Vaccines In Development to Fight Infectious Diseases

PhRMA  |  Press Release

Ten separate treatments for anthrax and three for smallpox are in development.
https://www.phrma.org/press-release/nearly-400-medicines-and-vaccines-in-development-to-fight-infectious-diseases

High Coinsurance on Specialty Tiers

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/high-coinsurance-on-specialty-tiers

Dr. William Chin to Lead Science & Regulatory Affairs

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.
https://www.phrma.org/press-release/dr-william-chin-to-lead-phrma-science-and-regulatory-affairs

The Time Has Arrived for Patent Reform

PhRMA  |  Blog Post

The bill (S23) would also encourage a positive environment for developing ideas that become life-changing innovations.
http://catalyst.phrma.org/the-time-has-arrived-for-patent-reform

Charles River Associates Releases Updated HTA Comparison Report

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested more than $550 billion in the search for new treatments and cures, including an estimated $51.1 billion in 2013 alone.
https://www.phrma.org/press-release/charles-river-associates-releases-updated-hta-comparison-report

New Study Examines Clinical Pathways: An Overview of Current Practices and Potential Implications for Patients, Payers, and Providers

PhRMA  |  Blog Post

With so much variation in development processes and more payers using financial incentives to drive pathway compliance, patient advocates and physicians alike are raising concerns that pathway programs could negatively impact patient choice and create barriers to accessing treatments designated as off-pathway.   
http://catalyst.phrma.org/new-study-examines-clinical-pathways-an-overview-of-current-practices-and-potential-implications-for-patients-payers-and-providers

Sir Andrew Witty

PhRMA  |  Biography

Andrew has a Joint Honours BA in Economics from the University of Nottingham.
https://www.phrma.org/biography/sir-andrew-witty

Principles On Responsible Sharing of Truthful and Non-Misleading Information About Medicines with Health Care Professionals and Payers

PhRMA  |  Codes & Guidelines

The principles pertain primarily to data and information outside of FDA-approved labeling, and are intended to establish responsible, science-based parameters for accurate and trusted sharing. 
https://www.phrma.org/codes-and-guidelines/principles-on-responsible-sharing-of-truthful-and-non-misleading-information-about-medicines-with-health-care-professionals-and-payers

Scott LaGanga to Lead PhRMA State Advocacy; Shannon Graham to Lead Strategic Alliances

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.
https://www.phrma.org

The Biopharmaceutical Research and Development Process

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/the-biopharmaceutical-research-and-development-process

Medicines in Development

PhRMA  |  From PhRMA

Medications are transforming many cancers into treatable conditions, reducing the impact of cardiovascular disease, offering new options for patients with hard-to-treat diseases like Alzheimer’s and Parkinson’s, and fighting even the rarest conditions.
https://www.phrma.org/science/in-the-pipeline/medicines-in-development

You have reviewed the first 300 results out of 2649. Each page contains 25 results. You're on page 12.

prev 7 8 9 10 11 12 next